{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:10:07Z","timestamp":1759849807237,"version":"build-2065373602"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011272","name":"FP7 Health","doi-asserted-by":"publisher","award":["601852"],"award-info":[{"award-number":["601852"]}],"id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003123","name":"Fetal Medicine Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003123","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Racial and Ethnic Health Disparities"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To compare pre-eclampsia screening strategies among Black vs. White ethnicity women.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using data from prospective non-intervention cohort studies in Europe, we evaluated pre-eclampsia risk in singleton pregnancies. Risk was determined by clinical risk factor screening (\u2018clinical\u2019), \u2018clinical\u2019 with Black ethnicity as a moderate-risk factor (\u2018clinical-modified\u2019), and the Fetal Medicine Foundation competing-risks model at 11\u201313\u00a0weeks\u2019 gestation (\u2018model<jats:sub>11-13<\/jats:sub> \u2018 for preterm pre-eclampsia) and 35\u201336\u00a0weeks (\u2018model<jats:sub>35-36<\/jats:sub> \u2018 for late preterm\/term pre-eclampsia). To compare screening performance, models\u2019 screen-positive rates were adjusted to match \u2018clinical\u2019 screening.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>At 11\u201313\u00a0weeks, 61,174 pregnancies were screened; preterm pre-eclampsia occurred in 493 (0.8%). At an overall 11.2% screen-positive-rate, \u2018model<jats:sub>11-13<\/jats:sub> \u2018 (vs. \u2018clinical\u2019) detection of preterm pre-eclampsia almost doubled for Black (88.0% from 46.4%) and White (66.4% from 36.7%) women. For \u2018clinical-modified\u2019, the overall screen-positive-rate was 18.5% and the detection rate for \u2018model<jats:sub>11-13<\/jats:sub> \u2018 (vs. \u2018clinical-modified\u2019) was 94.0% from 85.0% for Black women, and 77.3% from 36.7% for White. At 35\u201336\u00a0weeks, 29,035 pregnancies were screened; subsequent pre-eclampsia occurred in 654 (2.3%). At an overall 10.9% screen-positive-rate, \u2018model<jats:sub>35-36<\/jats:sub> \u2018 (vs. \u2018clinical\u2019) detection of pre-eclampsia more than doubled for both Black (74.8% from 26.2%) and White (69.6% from 33.1%) women. For \u2018clinical-modified\u2019, the overall screen-positive-rate was 15.5% and the detection rate for \u2018model<jats:sub>35-36<\/jats:sub> \u2018 (vs. \u2018clinical-modified\u2019) was 84.1% from 85.0% for Black women, and 78.5% from 33.1% for White.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The screening performance of the competing-risks model is superior to that of clinical risk factor screening without and with addition of Black ethnicity as a moderate clinical risk factor.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s40615-025-02680-7","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:29:28Z","timestamp":1759847368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimising Pre-Eclampsia Screening in Black Women; a Secondary Analysis of Data from Non-Intervention Screening Studies"],"prefix":"10.1007","author":[{"given":"Anastasija","family":"Arechvo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Argyro","family":"Syngelaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"D\u00f6bert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Nektaria","family":"Varouxaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Yi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liona","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"von Dadelszen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kypros H.","family":"Nicolaides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-610X","authenticated-orcid":false,"given":"Laura A.","family":"Magee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"19","key":"2680_CR1","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMra2109523","volume":"386","author":"LA Magee","year":"2022","unstructured":"Magee LA, Nicolaides KH, von Dadelszen P. Preeclampsia. N Engl J Med. 2022;386(19):1817\u201332.","journal-title":"N Engl J Med"},{"issue":"12","key":"2680_CR2","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/1471-0528.17240","volume":"129","author":"A Arechvo","year":"2022","unstructured":"Arechvo A, Voicu D, Gil MM, Syngelaki A, Akolekar R, Nicolaides KH. Maternal race and pre-eclampsia: cohort study and systematic review with meta-analysis. BJOG. 2022;129(12):2082\u201393.","journal-title":"BJOG"},{"key":"2680_CR3","unstructured":"NICE. Hypertension in preganncy: diagnosis and management. NICE guidance [NG133]. https:\/\/www.nice.org.uk\/guidance\/ng133. 2019. Last updated 17 Apr 2023."},{"issue":"7","key":"2680_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","volume":"377","author":"DL Rolnik","year":"2017","unstructured":"Rolnik DL, Wright D, Poon LC, O\u2019Gorman N, Syngelaki A, de Paco MC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613\u201322.","journal-title":"N Engl J Med"},{"issue":"6","key":"2680_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/uog.19039","volume":"51","author":"MY Tan","year":"2018","unstructured":"Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018;51(6):743\u201350.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2680_CR6","doi-asserted-by":"crossref","unstructured":"Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol. 2015;213(1):62 e1- e10.","DOI":"10.1016\/j.ajog.2015.02.018"},{"key":"2680_CR7","doi-asserted-by":"crossref","unstructured":"O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11\u201313 weeks gestation. Am J Obstet Gynecol. 2016;214(1):103 e1- e12.","DOI":"10.1016\/j.ajog.2015.08.034"},{"key":"2680_CR8","doi-asserted-by":"crossref","unstructured":"Wright D, Wright A, Nicolaides KH. The competing risk approach for prediction of preeclampsia. Am J Obstet Gynecol. 2020;223(1):12\u201323 e7.","DOI":"10.1016\/j.ajog.2019.11.1247"},{"issue":"3","key":"2680_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/uog.22140","volume":"56","author":"A Mazer Zumaeta","year":"2020","unstructured":"Mazer Zumaeta A, Wright A, Syngelaki A, Maritsa VA, Bardani E, Nicolaides KH. Screening for trisomy at 11\u201313 weeks\u2019 gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both. Ultrasound Obstet Gynecol. 2020;56(3):408\u201315.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"2","key":"2680_CR10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/uog.19112","volume":"52","author":"MY Tan","year":"2018","unstructured":"Tan MY, Syngelaki A, Poon LC, Rolnik DL, O\u2019Gorman N, Delgado JL, et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11\u201313 weeks\u2019 gestation. Ultrasound Obstet Gynecol. 2018;52(2):186\u201395.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"2680_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/uog.15812","volume":"48","author":"S Andrietti","year":"2016","unstructured":"Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH. Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35\u201337 weeks\u2019 gestation. Ultrasound Obstet Gynecol. 2016;48(1):72\u20139.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"2680_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/uog.24789","volume":"59","author":"M Dobert","year":"2022","unstructured":"Dobert M, Wright A, Varouxaki AN, Mu AC, Syngelaki A, Rehal A, et al. STATIN trial: predictive performance of competing-risks model in screening for pre-eclampsia at 35\u201337 weeks\u2019 gestation. Ultrasound Obstet Gynecol. 2022;59(1):69\u201375.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2680_CR13","unstructured":"MBRRACE-UK. Saving lives, improving mothers\u2019 care state of the nation report: surveillance findings and lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths from thrombosis and thromboembolism, malignancy and ectopic pregnancy 2020\u20132022, and morbidity findings for recent migrants withlanguage difficulties. Oxford: National Perinatal Epidemiology Unit, University of Oxford. 2024."},{"issue":"6","key":"2680_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/uog.17399","volume":"49","author":"N O'Gorman","year":"2017","unstructured":"O\u2019Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, et al. Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11\u201313 weeks\u2019 gestation. Ultrasound Obstet Gynecol. 2017;49(6):751\u20135.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2680_CR15","doi-asserted-by":"crossref","unstructured":"von Dadelszen P, Syngelaki A, Wright A, Akolekar R, Magee LA, Wright D, et al. The implications of the Fetal Medicine Foundation 35- to 36-week preeclampsia prediction competing-risk model on timing of birth. Am J Obstet Gynecol. 2023;228(4):457 e1- e7.","DOI":"10.1016\/j.ajog.2022.09.047"},{"issue":"7491","key":"2680_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1136\/bmj.38380.674340.E0","volume":"330","author":"K Duckitt","year":"2005","unstructured":"Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330(7491):565.","journal-title":"BMJ"},{"key":"2680_CR17","doi-asserted-by":"crossref","unstructured":"ACOG practice bulletin no. 202 summary: Gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133(1):1.","DOI":"10.1097\/AOG.0000000000003021"},{"key":"2680_CR18","doi-asserted-by":"crossref","unstructured":"Chaemsaithong P, Pooh RK, Zheng M, Ma R, Chaiyasit N, Tokunaka M, et al. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population. Am J Obstet Gynecol. 2019;221(6):650 e1- e16.","DOI":"10.1016\/j.ajog.2019.09.041"},{"issue":"4","key":"2680_CR19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/uog.26233","volume":"62","author":"D Cuenca-Gomez","year":"2023","unstructured":"Cuenca-Gomez D, de Paco MC, Rolle V, Valino N, Revello R, Adiego B, et al. Performance of first-trimester combined screening for preterm pre-eclampsia: findings from cohort of 10 110 pregnancies in Spain. Ultrasound Obstet Gynecol. 2023;62(4):522\u201330.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"6","key":"2680_CR20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/uog.26183","volume":"61","author":"I Riishede","year":"2023","unstructured":"Riishede I, Rode L, Sperling L, Overgaard M, Ravn JD, Sandager P, et al. Pre-eclampsia screening in Denmark (PRESIDE): national validation study. Ultrasound Obstet Gynecol. 2023;61(6):682\u201390.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"2680_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000335366","volume":"31","author":"LC Poon","year":"2012","unstructured":"Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH. Protocol for measurement of mean arterial pressure at 11\u201313 weeks\u2019 gestation. Fetal Diagn Ther. 2012;31(1):42\u20138.","journal-title":"Fetal Diagn Ther"},{"issue":"5","key":"2680_CR22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/uog.5157","volume":"30","author":"W Plasencia","year":"2007","unstructured":"Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2007;30(5):742\u20139.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2680_CR23","doi-asserted-by":"crossref","unstructured":"American College of O, Gynecologists' Committee on Practice B-O. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. 2020;135(6):e237-e60.","DOI":"10.1097\/AOG.0000000000003891"},{"issue":"1","key":"2680_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/uog.19073","volume":"52","author":"KH Nicolaides","year":"2018","unstructured":"Nicolaides KH, Wright D, Syngelaki A, Wright A, Akolekar R. Fetal medicine foundation fetal and neonatal population weight charts. Ultrasound Obstet Gynecol. 2018;52(1):44\u201351.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2680_CR25","doi-asserted-by":"crossref","unstructured":"Wright D, Tan MY, O\u2019Gorman N, Poon LC, Syngelaki A, Wright A, et al. Predictive performance of the competing risk model in screening for preeclampsia. Am J Obstet Gynecol. 2019;220(2):199 e1- e13.","DOI":"10.1016\/j.ajog.2018.11.1087"},{"key":"2680_CR26","doi-asserted-by":"crossref","unstructured":"Goadsby J, Syngelaki A, Magee LA, et al. Preeclampsia prevention by timed birth at term (PREVENT-PE): a randomised trial. Presented at the Action on Pre-eclampsia Annual Conference 2024 https:\/\/action-on-pre-eclampsiaorguk\/professional-area\/annual-conference\/. 2024.","DOI":"10.21203\/rs.3.rs-5224465\/v1"},{"issue":"11","key":"2680_CR27","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1056\/NEJMp2311019","volume":"390","author":"DA Sacks","year":"2024","unstructured":"Sacks DA, Incerpi MH. Of aspirin, preeclampsia, and racism. N Engl J Med. 2024;390(11):968\u20139.","journal-title":"N Engl J Med"},{"key":"2680_CR28","doi-asserted-by":"crossref","unstructured":"Poon LC, Wright D, Rolnik DL, Syngelaki A, Delgado JL, Tsokaki T, et al. Aspirin for evidence-based preeclampsia prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. Am J Obstet Gynecol. 2017;217(5):585 e1- e5.","DOI":"10.1016\/j.ajog.2017.07.038"},{"issue":"22","key":"2680_CR29","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1001\/jama.2023.7398","volume":"329","author":"M Mendoza","year":"2023","unstructured":"Mendoza M, Carreras E, Suy A. Aspirin discontinuation in pregnancies at high risk of preterm preeclampsia-reply. JAMA. 2023;329(22):1988\u20139.","journal-title":"JAMA"},{"issue":"1","key":"2680_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/1471-0528.17320","volume":"131","author":"T Elawad","year":"2024","unstructured":"Elawad T, Scott G, Bone JN, Elwell H, Lopez CE, Filippi V, et al. Risk factors for pre-eclampsia in clinical practice guidelines: comparison with the evidence. BJOG. 2024;131(1):46\u201362.","journal-title":"BJOG"},{"issue":"1","key":"2680_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/uog.26084","volume":"61","author":"A Arechvo","year":"2023","unstructured":"Arechvo A, Wright A, Syngelaki A, von Dadelszen P, Magee LA, Akolekar R, et al. Incidence of pre-eclampsia: effect of deprivation. Ultrasound Obstet Gynecol. 2023;61(1):26\u201332.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"6","key":"2680_CR32","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/uog.26105","volume":"60","author":"Z Ansbacher-Feldman","year":"2022","unstructured":"Ansbacher-Feldman Z, Syngelaki A, Meiri H, Cirkin R, Nicolaides KH, Louzoun Y. Machine-learning-based prediction of pre-eclampsia using first-trimester maternal characteristics and biomarkers. Ultrasound Obstet Gynecol. 2022;60(6):739\u201345.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"2680_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/1471-0528.17296","volume":"130","author":"A Wright","year":"2023","unstructured":"Wright A, von Dadelszen P, Magee LA, Syngelaki A, Akolekar R, Wright D, et al. Effect of race on the measurement of angiogenic factors for prediction and diagnosis of pre-eclampsia. BJOG. 2023;130(1):78\u201387.","journal-title":"BJOG"},{"issue":"2","key":"2680_CR34","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/1471-0528.17598","volume":"131","author":"D Nzelu","year":"2024","unstructured":"Nzelu D, Palmer T, Stott D, Pandya P, Napolitano R, Casagrandi D, et al. First trimester screening for pre-eclampsia and targeted aspirin prophylaxis: a cost-effectiveness cohort study. BJOG. 2024;131(2):222\u201330.","journal-title":"BJOG"},{"issue":"5","key":"2680_CR35","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/uog.22193","volume":"58","author":"F Park","year":"2021","unstructured":"Park F, Deeming S, Bennett N, Hyett J. Cost-effectiveness analysis of a model of first-trimester prediction and prevention of preterm pre-eclampsia compared with usual care. Ultrasound Obstet Gynecol. 2021;58(5):688\u201397.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2680_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.preghy.2021.06.012","volume":"25","author":"A Dubon Garcia","year":"2021","unstructured":"Dubon Garcia A, Devlieger R, Redekop K, Vandeweyer K, Verlohren S, Poon LC. Cost-utility of a first-trimester screening strategy versus the standard of care for nulliparous women to prevent pre-term pre-eclampsia in Belgium. Pregnancy Hypertens. 2021;25:219\u201324.","journal-title":"Pregnancy Hypertens"},{"issue":"2","key":"2680_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/uog.19076","volume":"53","author":"D Ortved","year":"2019","unstructured":"Ortved D, Hawkins TL, Johnson JA, Hyett J, Metcalfe A. Cost-effectiveness of first-trimester screening with early preventative use of aspirin in women at high risk of early-onset pre-eclampsia. Ultrasound Obstet Gynecol. 2019;53(2):239\u201344.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"3","key":"2680_CR38","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/AOG.0000000000003413","volume":"134","author":"D Mallampati","year":"2019","unstructured":"Mallampati D, Grobman W, Rouse DJ, Werner EF. Strategies for prescribing aspirin to prevent preeclampsia: a cost-effectiveness analysis. Obstet Gynecol. 2019;134(3):537\u201344.","journal-title":"Obstet Gynecol"},{"key":"2680_CR39","unstructured":"NICE. Hypertension in pregnancy. The management of hypertensive disorders during pregnancy. NICE clinical guideline 107. 2010."}],"container-title":["Journal of Racial and Ethnic Health Disparities"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-025-02680-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40615-025-02680-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-025-02680-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:29:31Z","timestamp":1759847371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40615-025-02680-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":39,"alternative-id":["2680"],"URL":"https:\/\/doi.org\/10.1007\/s40615-025-02680-7","relation":{},"ISSN":["2197-3792","2196-8837"],"issn-type":[{"value":"2197-3792","type":"print"},{"value":"2196-8837","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies were Research Ethics Committee (REC)-approved (London-Dulwich REC, 01\/04\/2003, ref: 02\u201303-033(7, 15); London-Fulham REC, 12\/11\/2013, ref: 13\/LO\/1479(14); London-Surrey Borders REC, 22\/12\/2015, ref: 15\/LO\/2161(5).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All women provided written informed consent for participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors reviewed the final version of the manuscript which they approved for submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors report no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}